Key result
Atorvastatin 20 mg daily for 12 weeks significantly reduced HOMA-β (240 vs 177; P<0.01) in women with PCOS, with no changes observed in the placebo group.
Why the study?
Does atorvastatin affect pancreatic β cell function (HOMA-β) in medication-naïve women with PCOS?
Population
40 medication-naïve women with polycystic ovary syndrome (PCOS)
Comparison
Atorvastatin 20 mg daily for 3 months, followed… vs Placebo for 3 months, followed by a 3-month…
Design
RCT, randomised, double-blind
Follow-up
6 months (3 months initial + 3 months extension)
Authors
Loading...
Atorvastatin may reduce β-cell demand via improved insulin sensitivity in PCOS; extends statin metabolic effects beyond lipids in this population.
RCT (n=40)
Double-blind
randomised
Does atorvastatin affect pancreatic β cell function (HOMA-β) in medication-naïve women with PCOS?
p-value: p=<0.01
Atorvastatin treatment for 12 weeks in women with PCOS significantly reduced HOMA-β, likely reflecting a fall in β-cell requirement due to improved insulin resistance.
Sathyapalan et al. (2017) conducted an RCT in Polycystic ovary syndrome (PCOS) (n=40). Atorvastatin vs. Placebo was evaluated on Pancreatic β cell function using HOMA-β (p=<0.01). Atorvastatin 20 mg daily for 12 weeks significantly reduced HOMA-β (240 vs 177; P<0.01) in women with PCOS, with no changes observed in the placebo group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: